Expectations For Sanofi’s Dupixent Successor Drop On Latest Eczema Data
Disappointing efficacy from amlitelimab plus another safety signal have sunk the OX40L antagonist’s peak sales potential.
Scrip - March 30, 2026

Former CMS Top Official Says Brain-Computer Interface Development Outpaces CMS Coverage
Lee Fleisher, former chief medical officer at CMS, fears that lack of insurance coverage framework for implantable brain-computer interfaces could leave these technologies out of reach for patients.
Medtech Insight - March 30, 2026

Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - March 30, 2026

Orkla Health Seeks Stable Growth But M&A Remains On Cards
Orkla Health pledges to "assess and carry out" M&A but achieving sustainable sales and earnings growth remains its immediate priority.
HBW Insight - March 30, 2026

German OTC Market Rescued By Online Pharmacy and Prevention in 2025
Germany’s OTC market in 2025 did not grow because consumers bought more products. It grew because they bought different ones, and increasingly did so online.
HBW Insight - March 30, 2026

Viatris Bets On Value-Added Medicines To Boost Growth
Viatris is accelerating its shift to higher-margin, value-added medicines, combining near-term launches, cost restructuring and disciplined dealmaking to drive sustained growth through 2030, while leveraging a stable generics base and advancing a late-stage innovative pipeline.
Generics Bulletin - March 30, 2026

Obesity Beyond GLP-1s: Oral Formulations Take Center Stage
In this series of articles, we look at different approaches beyond the injectable GLP-1s that could determine the obesity drug landscape in the coming years.
Scrip - March 30, 2026

Amgen’s Repatha Slashes Heart Event Risk in Early?Stage Patients
New data suggest Repatha could expand into earlier preventive use, supported by meaningful LDL?C reductions in patients without established atherosclerosis.
Scrip - March 30, 2026

Neion Bio Strikes Initial Biosimilars Deal For Its Egg-Based Platform
Announcing itself with a multi-product biosimilar deal, newly-unveiled biotech firm Neion Bio is planning to revolutionize the market with a proprietary technology platform that uses genetic engineering tools to manufacture recombinant biologics in eggs.
Generics Bulletin - March 30, 2026

Five-Minute Podcast: ‘UK Must Align More With EU’
Browne Jacobson partner Gerard Hanratty spoke at BioWales 2026 to give a legal firm’s perspective on how the UK should evolve its medtech regulatory system, pursue global harmonization and take opportunities to embed best practice AI.
Medtech Insight - March 30, 2026

Outlook Raises Cash As FDA Setbacks Cloud Future
Outlook Therapeutics has raised $23m through debt and equity financings as it continues to grapple with repeated FDA setbacks for its ophthalmic bevacizumab candidate, leaving its US approval pathway uncertain despite growing traction in Europe.
Generics Bulletin - March 30, 2026

Adapt To Survive: Private Hospitals In A High-Pressure Landscape
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
Medtech Insight - March 30, 2026

Over The Counter: Why Longevity Is The Next OTC Opportunity, With Euromonitor’s Magda Starula
In this episode of HBW Insight's Over the Counter podcast, Euromonitor’s Magda Starula explains how longevity is shifting from wellness buzzword to a practical growth framework for consumer healthcare.
HBW Insight - March 30, 2026

M&A: South Korean Firms Shift To Factories Before Pipelines
South Korean pharma firms are shifting M&A focus from drug pipelines to manufacturing assets, seeking immediate production capacity and stable revenue amid high interest rates, tighter biotech financing, and global supply chain pressures.
In Vivo - March 30, 2026

BioBytes: AI-Related Deals In Q4 ‘24
The last quarter of 2024 was flush with venture financings for biotechs finding novel ways to incorporate AI into their processes.
In Vivo - March 30, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Merck’s case for Terns and more deals; Boehringer’s warning on innovation-unfriendly Europe; how Kelun-Merck pact changed China deal-making; neuroscience R&D regains ground; and new US LDL-C guidelines and drug costs.
Scrip - March 30, 2026

Insilico, Lilly In New Early-Stage Partnership Valued At Up To $2.75bn
Insilico Medicine and Eli Lilly strike another deal, this time giving the US giant global rights to a set of undisclosed preclinical assets at the Chinese firm.
Scrip - March 30, 2026

Not Just Hype: Multiple Chinese Firms Unveil Asset Progress In Weight Reduction
From once-daily and weekly oral small molecules to monthly injectable GLP-1R agonists and non-incretin candidates, multiple Chinese firms are rapidly progressing their programs in weight reduction.
Scrip - March 30, 2026